EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis

Ibon Eguiluz-Gracia iD, Rebecca V Parkin iD, Janice A Layhadi iD, Elizabeth Palmer iD, Xun Meng iD, Rongfei Zhu iD, Umit Sahiner iD, Stephen R Durham iD, Maria Jose Torres iD, Cristobalina Mayorga iD, Carmen Rondon iD, Mohamed H Shamji iD

Allergy · 2024

DOI: 10.1111/all.16083 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2024. Verfasst von Ibon Eguiluz-Gracia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, IBIMA-Hospital Regional Universitario de Málaga-ARADyAL, UMA, Málaga, Spain. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Allergens, Pollen, Poaceae. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Imperial Biomedical Research Centre, Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness, Regional Ministry of Education of Andalucia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Local allergic rhinitis (LAR) is defined by chronic nasal symptoms, absence of atopy, positive nasal allergen challenge (NAC) and a good response to subcutaneous allergen immunotherapy (SCIT). We sought to investigate SCIT capacity to induce local and systemic blocking antibodies in LAR patients.

Methods

A RDBPC study of grass SCIT was performed, with participants receiving either SCIT (Group A; n = 10) or placebo (Group B; n = 14) in the first 6 months. Both groups subsequently received SCIT for 12 months at Year 2. Nasal and serum antibodies (IgG 4 , IgA 1 and IgA 2 ) and their inhibitory capacity were measured at multiple timepoints.

Results

The allergen concentration tolerated increased significantly at 6 months (Group A; p = .047) and 24 months (Group B; p = .049) compared with baseline and persisted until the end of the study. Induction of serum sIgA 1 to Phl p was seen in Groups A and B, albeit the former being induced earlier (1.71‐fold, p = .027). A significant induction in sIgG 4 to Phl p 1 and 5 was observed in serum of Group A ( p = .047 and p = .0039) and sIgA 2 to Phl p in Group B ( p = .032 and p = .0098) at 18 and 24 months, respectively. Both local and systemic blocking antibodies can inhibit allergen–IgE complexes binding to CD23 on B cells, and this correlated with level of allergen tolerated intra‐nasally in Group A (serum; 𝜌 = −.47, p = .0006, nasal; 𝜌 = −.38, p = .0294).

Conclusions

Grass pollen SCIT induced functional systemic blocking antibodies that correlate with the concentration of allergen tolerated following NAC, highlighting their potential as a biomarker of SCIT in LAR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicAllergensPollenPoaceaeRhinitis, AllergicHumansMaleFemaleAdultMiddle AgedAntibodies, NeutralizingYoung AdultNasal Provocation TestsAdministration, IntranasalTreatment OutcomeImmunoglobulin ERhinitis, Allergic, SeasonalInjections, Subcutaneous

Stichwörter der Autor:innen

IgA1IgA2IgE‐FABIgG4blocking antibodieslocal allergic rhinitissubcutaneous immunotherapy

Substanzen

AllergensAntibodies, NeutralizingImmunoglobulin E

Autor:innen und Institutionen

  • Allergy Unit, IBIMA-Hospital Regional Universitario de Málaga-ARADyAL, UMA, Málaga, Spain.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • The MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.

ORCID-Profile: Ibon Eguiluz-Gracia, Rebecca V Parkin, Janice A Layhadi, Elizabeth Palmer, Xun Meng, Rongfei Zhu, Umit Sahiner, Stephen R Durham, Maria Jose Torres, Cristobalina Mayorga, Carmen Rondon, Mohamed H Shamji

Förderung

  • NIHR Imperial Biomedical Research Centre
  • Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness
  • Regional Ministry of Education of Andalucia
  • Instituto de Salud Carlos III

Zitieren

APA

Eguiluz-Gracia, I., Parkin, R. V., Layhadi, J. A., Palmer, E., Meng, X., Zhu, R., Sahiner, U., Durham, S. R., Torres, M. J., Mayorga, C., Rondon, C., & Shamji, M. H. (2024). Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis. Allergy. https://doi.org/10.1111/all.16083

Vancouver

Eguiluz-Gracia I, Parkin RV, Layhadi JA, Palmer E, Meng X, Zhu R, et al. Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis. Allergy. 2024. doi:10.1111/all.16083

BibTeX
@article{EguiluzGracia2024,
  author = {Eguiluz-Gracia, Ibon and Parkin, Rebecca V and Layhadi, Janice A and Palmer, Elizabeth and Meng, Xun and Zhu, Rongfei and Sahiner, Umit and Durham, Stephen R and Torres, Maria Jose and Mayorga, Cristobalina and Rondon, Carmen and Shamji, Mohamed H},
  title = {Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.16083}
}
Kostenlos starten →